EVOTEC SE ADR 1/2 O.N. Asset Resilience Ratio
EVOTEC SE ADR 1/2 O.N. asset resilience ratio. EVOTEC SE ADR 1/2 O.N. (EVTA) has an Asset Resilience Ratio of 3.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EVTA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of EVOTEC SE ADR 1/2 O.N. (2021–2025)
Asset resilience ratio of EVOTEC SE ADR 1/2 O.N. from 2021 to 2025. This chart shows how EVOTEC SE ADR 1/2 O.N.'s Asset Resilience Ratio has changed over time. Read EVTA current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down EVOTEC SE ADR 1/2 O.N.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see EVTA asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €61.23 Million | 3.57% |
| Total Liquid Assets | €61.23 Million | 3.57% |
Asset Resilience Insights
- Limited Liquidity: EVOTEC SE ADR 1/2 O.N. maintains only 3.57% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
EVOTEC SE ADR 1/2 O.N. Industry Peers by Asset Resilience Ratio
Compare EVOTEC SE ADR 1/2 O.N.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
EVOTEC SE ADR 1/2 O.N. Asset Resilience Ratio by Year (2021–2025)
EVOTEC SE ADR 1/2 O.N. asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for EVOTEC SE ADR 1/2 O.N..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.57% | €61.23 Million ≈ $71.58 Million |
€1.71 Billion ≈ $2.00 Billion |
-1.16pp |
| 2024-12-31 | 4.73% | €90.41 Million ≈ $105.70 Million |
€1.91 Billion ≈ $2.24 Billion |
+0.59pp |
| 2023-12-31 | 4.14% | €93.20 Million ≈ $108.96 Million |
€2.25 Billion ≈ $2.63 Billion |
-9.45pp |
| 2022-12-31 | 13.58% | €306.61 Million ≈ $358.46 Million |
€2.26 Billion ≈ $2.64 Billion |
+6.46pp |
| 2021-12-31 | 7.12% | €159.17 Million ≈ $186.09 Million |
€2.24 Billion ≈ $2.61 Billion |
-- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more